Breast Neoplasms Clinical Trial
Official title:
A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors
Verified date | March 2022 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive and negative breast and gastric cancer (HER2 positive only and gastric were studied in Part 1A only). The study will expand to look at selected doses in patients with HER2 positive and negative breast cancer.
Status | Completed |
Enrollment | 95 |
Est. completion date | August 31, 2021 |
Est. primary completion date | August 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - HER2 positive breast cancer or gastric cancer that is resistant to standard therapy or for which no standard therapy is available (Part 1A only) - HER2 positive and negative breast cancer (Part 2A) - HER2 negative breast cancer (Part 1B & Part 2B) - Performance status of 0 or 1 - Adequate bone marrow, kidney and liver function Exclusion Criteria: - Known CNS disease including, but not limited to, metastases - History of exposure to certain cumulative doses of anthracyclines - Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy - Active and clinically significant bacterial, fungal, or viral infection - Abnormal cardiac function defined by a LVEF <50% by ECHO or MUGA - Patients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseases |
Country | Name | City | State |
---|---|---|---|
Australia | Chris O'Brien Lifehouse | Camperdown | New South Wales |
Australia | Macquarie University | Macquarie University | New South Wales |
Italy | Divisione di Cardiologia - Istituto Europeo di Oncologia Divisione di Medicina Nucleare | Milano | MI |
Italy | Fondazione IRCCS, Istituto Nazionale dei Tumori | Milano | MI |
Italy | Istituto Europeo di Oncologia | Milano | MI |
Italy | Azienda Socio-Sanitaria Territoriale Monza | Monza | MB |
Italy | Istituto Clinico Humanitas U. O. Oculistica | Razzano | Milan |
Korea, Republic of | National Cancer Center | Goyang-si | Gyeonggi-do |
Korea, Republic of | Gachon University Gil Medical Center | Incheon | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | Gyeonggi-do |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | |
Russian Federation | LLC "Clinica UZI 4D" | Pyatigorsk | Stavropol Region |
Russian Federation | Private Healthcare Institution "Clinical hospital "RZD-Medicine" of Saint-Petersburg | Saint-Petersburg | |
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital Universitario Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario Fundación Jiménez Díaz | Madrid | |
Spain | Hospital Universitario HM Sanchinarro | Madrid | |
Spain | Hospital Universitario Quirón Madrid | Pozuelo de Alarcón | Madrid |
United States | Northside Hospital Inc.- GCS/Athens | Athens | Georgia |
United States | Atlanta Cancer Care - Atlanta | Atlanta | Georgia |
United States | Northside Hospital | Atlanta | Georgia |
United States | Northside Hospital, Inc. - GCS/Northside | Atlanta | Georgia |
United States | Northside Hospital,Inc.-GCS /Blairsville | Blairsville | Georgia |
United States | Northside Hospital, Inc. - GCS/Canton | Canton | Georgia |
United States | Atlanta Cancer Care - Cumming | Cumming | Georgia |
United States | Northside Hospital, Inc.-GCS/Stemmer | Decatur | Georgia |
United States | Suburban Hematology-Oncology Associates - Duluth | Duluth | Georgia |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Atlanta Cancer Care - Lake Spivey | Jonesboro | Georgia |
United States | Suburban Hematology-Oncology Associates- Lawrenceville | Lawrenceville | Georgia |
United States | Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California |
United States | UCLA Health (main campus) | Los Angeles | California |
United States | UCLA Hematology/Oncology | Los Angeles | California |
United States | Northside Hospital, Inc. - GCS/Macon | Macon | Georgia |
United States | Northside Hospital, Inc. GCS/Kennestone | Marietta | Georgia |
United States | Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska |
United States | University of Utah, Huntsman Cancer Hospital | Salt Lake City | Utah |
United States | University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah |
United States | Santa Monica - UCLA Medical Center and Orthopaedic Hospital | Santa Monica | California |
United States | UCLA Dept of Medicine - Hematology/Oncology, Santa Monica | Santa Monica | California |
United States | UCLA Health, Santa Monica | Santa Monica | California |
United States | Banner-University Medical Center Tucson | Tucson | Arizona |
United States | The University of Arizona Cancer Center | Tucson | Arizona |
United States | The University of Arizona Cancer Center - North Campus | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Australia, Italy, Korea, Republic of, Russian Federation, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with Dose-Limiting Toxicities (DLTs) | First cycle DLTs in order to determine the maximum tolerated dose of monotherapy. | Part 1A: Baseline through Day 21; Part 1B: Baseline through Day 28 | |
Primary | Percentage of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) | Assessment of all available safety data in order to determine the safety and tolerability of monotherapy and combination therapy | Part 1 and Part 2: Baseline through LSLV (up to approximately 2 years) | |
Primary | Number of participant with objective response | To investigate preliminary antitumor activity | Part 2: Baseline through LSLV (up to approximately 2 years) | |
Primary | Duration of Response (DR) | To investigate preliminary antitumor activity | Part 2: Baseline through LSLV (up to approximately 2 years) | |
Primary | Progression-Free Survival (PFS) | To investigate preliminary antitumor activity | Part 2: Baseline through LSLV (up to approximately 2 years) | |
Primary | Time to Tumor Progression (TTP) | To investigate preliminary antitumor activity | Part 2: Baseline through LSLV (up to approximately 2 years) | |
Secondary | Maximum Observed Concentration (Cmax) - Part 1A | To understand single and multiple dose parameters | Cycle 1 Day 1: 0, 1, 4, and 24 hours, Day 4, Day 8 and Day 15, Cycle 2 Day 1 0 and 1 hour, Cycle 3 Day 1 0 and 1 hour, Cycle 4 Day 1 0, 1, 4 and 24 hour, Day 4, Day 8, Day 15, and Day 1 0 and 1 hour of subsequent cycles (cycle is 21 days) up to 24 months | |
Secondary | Maximum Observed Concentration (Cmax) - Part 2A | To understand single and multiple dose parameters | Cycles 1 & 4 on Day 1 at 0, 1, 4 hours, and on Day 15; Cycles 2 & 3 on Day 1 at 0 & 1 hour; Every subsequent cycle pn Day 1 at 0 and 1 hour (cycle is 21 days) up to 24 months | |
Secondary | Maximum Observed Concentration (Cmax) Part B | To understand single and multiple dose parameters | Cycles 1 & 4 on Day 1 at 0, 1, 4, & 24 hours, Day 4, Day 8 & Day 15 at 0 & 1 hour; Cycles 2 & 3 on Day 1 at 0 & 1 hour, Cycles 2 & 3 on Day 15 at 0 & 1 hour; Every subsequent cycle on Day 1 at 0 & 1 hour (cycle is 28 days) up to 24 months | |
Secondary | Time to reach maximum observed concentration (Tmax) - Part 1A | To understand single and multiple dose parameters | Cycles 1 & 4 Day 1: 0, 1, 4, and 24 hours, Day 4, Day 8 and Day 15, Cycles 2 & 3 Day 1: 0 and 1 hour, and Day 1: 0 and 1 hour of subsequent cycles (cycle is 21 days) up to 24 months | |
Secondary | Time to reach maximum observed concentration (Tmax) - Part 2A | To understand single and multiple dose parameters | Cycles 1 & 4 on Day 1 at 0, 1, 4 hours, and on Day 15; Cycles 2 & 3 on Day 1 at 0 & 1 hour; Every subsequent cycle pn Day 1 at 0 and 1 hour (cycle is 21 days) up to 24 months | |
Secondary | Time to reach maximum observed concentration (Tmax) - Part B | To understand single and multiple dose parameters | Cycles 1 & 4 Day 1: 0, 1, 4, and 24 hours, Day 4, Day 8 and Day 15, Cycles 2 & 3 Day 1: 0 and 1 hour, and Day 1: 0 and 1 hour of subsequent cycles (cycle is 28 days) up to 24 months | |
Secondary | Area under the curve from time zero to end of dosing interval (AUCtau) Part 1A | To understand single and multiple dose parameters | Cycle 1 Day 1 0, 1 4, and 24 hours, Day 4, Day 8 and Day 15, Cycle 2 Day 1 0 and 1 hour, Cycle 3 Day 1 0 and 1 hour, Cycle 4 Day 1 0, 1, 4 and 24 hour, Day 4, Day 8, Day 15, and Day 1 0 and 1 hour of subsequent cycles (cycle is 21 days) up to 24 months | |
Secondary | Area under the curve from time zero to end of dosing interval (AUCtau) Part 2A | To understand single and multiple dose parameters | Cycles 1 and 4: Day 1: 0, 1, 4 hours, and Day 15; Cycle 2 and 3, Day 1: 0 and 1 hour, and Day 1 at 0 and 1 hour of subsequent cycles (cycle is 21 days) up to 24 months | |
Secondary | Area under the curve from time zero to end of dosing interval (AUCtau) Part B | To understand single and multiple dose parameters | Cycles 1 and 4: Day 1: 0, 1, 4 hours, Day 2, Day 4, Day 8 and Day 15 at 0 and 1 hour; Cycle 2 and 3, Day 1: 0 and 1 hour and Day 15 at 0 and 1 hour, and Day 1 at 0 and 1 hour of subsequent cycles (cycle is 28 days) up to 24 months | |
Secondary | Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast) Part 1A | To understand single and multiple dose parameters | Cycle 1 & Cycle 4 Day 1: 0, 1, 4, & 24 hours, Day 4, Day 8 & Day 15, Cycles 2 & 3 Day 1: 0 & 1 hour, and Day 1 at 0 & 1 hour of subsequent cycles (cycle is 21 days) up to 24 months | |
Secondary | Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast) Part 2A | To understand single and multiple dose parameters | Cycle 1 & Cycle 4 Day 1: 0, 1, 4 hours, & Day 15, Cycles 2 & 3 Day 1: 0 & 1 hour, and Day 1 at 0 & 1 hour of subsequent cycles (cycle is 21 days) up to 24 months | |
Secondary | Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast) Part B | To understand single and multiple dose parameters | Cycle 1 & Cycle 4 Day 1: 0, 1, 4, & 24 hours, Day 4, Day 8 & Day 15, Cycles 2 & 3 Day 1: 0 & 1 hour, and Day 1 at 0 & 1 hour of subsequent cycles (cycle is 28 days) up to 24 months | |
Secondary | Incidence and titers of anti-drug antibodies Part A | To evaluate the immunogenicity of the drug | Cycle 1 Day 1, Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Day 1 of every subsequent cycle (each cycle is 21 days) up to 24 months | |
Secondary | Incidence and titers of anti-drug antibodies Part B | To evaluate the immunogenicity of the drug | Cycle 1 Day 1, Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Day 1 of every subsquent cycle (each cycle is 28 days) up to 24 months | |
Secondary | Incidence and titers of neutralizing antibodies Part A | To evaluate the immunogenicity of the drug | Cycle 1 Day 1, Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Day 1 of every subsquent cycle (each cycle is 21 days) up to 24 months | |
Secondary | Incidence and titers of neutralizing antibodies Part B | To evaluate the immunogenicity of the drug | Cycle 1 Day 1, Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Day 1 of every subsquent cycle (each cycle is 28 days) up to 24 months | |
Secondary | Number of participant with objective response | Document antitumor activity | Baseline and every 6 weeks (monotherapy) or every 8 weeks (combination therapy) until disease progression, unacceptable toxicity, or up to 24 months | |
Secondary | Progression-Free Survival (PFS) | Document antitumor activity | Baseline and every 6 weeks (monotherapy) or every 8 weeks (combination therapy) until disease progression, unacceptable toxicity, or up to 24 months | |
Secondary | HER2 expression level in patients with documented anti-tumor activity | Explore preliminary antitumor activity | Baseline and Cycle 3 Day 1 (for monotherapy: each cycle is 21 days; for combination therapy: each cycle is 28 days) | |
Secondary | Duration of Response (DR) | Document antitumor activity | Baseline and every 6 weeks (monotherapy) or every 8 weeks (combination therapy) until disease progression, unacceptable toxicity, or up to 24 months | |
Secondary | Time to Tumor Progression (TTP) | Document antitumor activity | Baseline and every 6 weeks (monotherapy) or every 8 weeks (combination therapy) until disease progression, unacceptable toxicity, or up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03698942 -
Delphinus SoftVueâ„¢ ROC Reader Study
|
||
Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A |